PluriPLUR +1.19%25 OCF Margin % is -2,701.80% as of Mar. 2026. GuruFocus rates PLUR with a GF Score™ of 25/100 and a GF Value™ of $6.46 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 959 Biotechnology companies, Pluri ranks worse than 84.78% on this metric.
OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Pluri's Cash Flow from Operations for the
three
months ended in Mar. 2026 was $-4.51 Mil. Pluri's Revenue for the
three
months ended in Mar. 2026 was $0.17 Mil. Therefore, Pluri's OCF Margin % for the quarter that ended in Mar. 2026 was -2,701.80%.
The historical rank and industry rank for Pluri's OCF Margin % or its related term are showing as below:
PLUR'
s OCF Margin % Range Over the Past 10 Years
Min: -114647.83 Med: -11781.42 Max: -650.58
Current: -1887.03
During the past 13 years, the highest OCF Margin % of Pluri was -650.58%. The lowest was -114647.83%. And the median was -11781.42%.
PLUR's OCF Margin % is ranked worse than 84.78% of 959
companies
in the Biotechnology industry
Industry Median: -66.52
vs PLUR: -1887.03
Pluri OCF Margin % Related Terms
Pluri OCF Margin % Historical Data
* Premium members only.
The historical data trend for Pluri's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Pluri's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pluri OCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pluri's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Pluri's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pluri (PLUR) has a OCF Margin % of -2,701.80% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Pluri and its competitors. According to the industry distribution chart, Pluri ranks #813 out of 959 companies in the Biotechnology industry, placing it in the top 84.8%.
Is Pluri's OCF Margin % too high?
Pluri's current OCF Margin % is -2,701.80%. Based on the distribution chart, Pluri ranks #813 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pluri has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Pluri's OCF Margin % compare to VTGN and PTN?
According to the Biotechnology industry distribution chart, Pluri ranks #813 out of 959 companies for OCF Margin %. This places Pluri in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Pluri and its competitors. Pluri's current OCF Margin % is -2,701.80%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pluri stock overvalued right now?
Based on GuruFocus' analysis, Pluri (PLUR) is currently considered Possible Value Trap. The stock's GF Value™ is $6.46, compared to a current price of $2.12 — trading 67.2% below its estimated fair value. The current OCF Margin % is -2,701.80%. Pluri's overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Pluri (PLUR), the current OCF Margin % is -2,701.80% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pluri (PLUR) Overvalued in 2026?
Based on GuruFocus' analysis, Pluri stock appears to be undervalued.
The current stock price of $2.12 is trading 67.2% below its estimated GF Value™ of $6.46.
GuruFocus considers Pluri to be Possible Value Trap.
Key valuation signals for PLUR:
OCF Margin %: -2,701.80%
GF Value™: $6.46 vs. price of $2.12 (67.2% below fair value)
No single metric tells the full story. See the PLUR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
25GF Score
Get the complete analysis for PLUR
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLUR has been successfully added to your 
